ALRN (Aileron Therapeutics, Inc.) Earnings per share for the last four quarters

Public company logo of Aileron Therapeutics Inc (ALRN)

Aileron Therapeutics' authority in developing targeted oncology therapies defines a trend where the relative YoY EPS growth over the last 12 months demonstrates a fresh parameter 40.40. US chemotherapy cell protection centers provide stability. The orphan status of the drugs guarantees the resilience of its positions, keeping patients within a specialized niche ecosystem.

ALRN Aileron Therapeutics, Inc. Earnings per share for the last twelve months (02/11/2024 - 11/18/2026)

Aileron - analytical breakdowns and key metrics (ALRN)

- business market valuation indicators:
Fundamental valuation:Aileron Therapeutics Inc (ALRN)
Signature product of Aileron Therapeutics Inc

This indicator measures the dynamics of net income per share over a rolling year, reflecting the actual pace of capitalization expansion. The metric allows an investor to assess cost management efficiency and the speed of business scaling. By analyzing the annual percentage growth of EPS TTM, one can identify asset overbought conditions or confirm a sustainable trend. For Aileron Therapeutics (ALRN), this indicator is critical during the development of radiation protective drugs. The success of innovative chemical protection converts directly into profit growth, confirming the commercial viability of the technology.

Competitor analysis for Aileron Therapeutics

Earnings per share for the trailing year GMAB (Genmab US)|EXEL (Exelixis) - Net earnings per share for the last 12 months|NUVL: Earnings per share for the last four quarters|KYMR (Kymera Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) ideayabio.com|Earnings per share for the last twelve months Enliven Therapeutics, Inc. (ELVN)|ORIC (ORIC Pharmaceuticals, Inc.) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) RLAY (Relay Therapeutics Inc)|Net earnings per share for the trailing year Nurix Pharma|Tyra Biosciences Inc - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Verastem|GLUE (Monte Rosa Therapeutics) - Net earnings per share for the last 12 months|CGEM: Earnings per share for the last four quarters|IMRX (immuneering.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months C4 Tx CCCC|Net earnings per share (EPS TTM) BDTX|Repare Therapeutics Inc. - Earnings per share for the last 12 months|PMV Pharmaceuticals, Inc. - Net earnings per share for the last 12 months|Earnings per share for the trailing year KPTI|PPCB: Net earnings per share for the last 12 months|Cyclacel Pharmaceuticals - Earnings per share for the last four quarters|AADI: Net earnings per share (EPS TTM)|Blueprint Medicines Corp. - Earnings per share for the trailing year|GLYC (GlycoMimetics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months SpringWorks Therapeutics Inc. SWTX